Treatment options for surgically resectable gastric cancer

Current Treatment Options in Oncology

Volumn 11, Issue 1-2, 2010, Pages 14-23

  Rajdev, Lakshmi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; HEAT SHOCK PROTEIN 90 INHIBITOR; METHOTREXATE; PACLITAXEL; PLACEBO; TRASTUZUMAB;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ADJUVANT THERAPY; ANOREXIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FLU LIKE SYNDROME; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GASTRECTOMY; HUMANS; RADIOTHERAPY; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 77956228703     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-010-0117-1     Document Type: Review

References (33)

1. RT Greenlee T Murray S Bolden PA Wingo 2000 Cancer statistics, 2000 CA Cancer J Clin 50 7 33 10.3322/canjclin.50.1.7 1:STN:280:DC%2BD3c7pvFWrug%3D%3D 10735013
2. JA Ajani 1998 Chemotherapy for gastric carcinoma: new and old options Oncology (Huntingt) 12 10 Suppl 7 44 47 1:STN:280:DyaK1M%2FkvVeitQ%3D%3D
3. LL Gunderson 2002 Gastric cancer: patterns of relapse after surgical resection Semin Radiat Oncol 12 150 161 10.1053/srao.2002.30817 11979416
4. LL Gunderson H Sosin 1982 Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy Int J Radiat Oncol Biol Phys 8 1 11 1:STN:280:DyaL387ktFOmsw%3D%3D 7061243
5. J Landry J Tepper W Wood, et al. 1986 Analysis of survival and local control following surgery for gastric cancer Int J Radiat Oncol Biol Phys 12 119
6. J Landry J Tepper W Wood, et al. 1990 Patterns of failure following curative resection of gastric carcinoma Int J Radiat Oncol Biol Phys 19 1357 1362 1:STN:280:DyaK3M%2Fos1Wntg%3D%3D 2262358
7. F Bozzetti E Marubini G Bonfanti, et al. 1999 Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial Ann Surg 230 170 178 10.1097/00000658-199908000-00006 1:STN:280:DyaK1Mznsl2guw%3D%3D 10450730
8. A Viste T Haugstvedt GE Eide, et al. 1988 Postoperative complications and mortality after surgery for gastric cancer Ann Surg 207 7 12 10.1097/00000658-198801000-00003 1:STN:280:DyaL1c7gsFKnuw%3D%3D 3337564
9. A Cuschieri S Weeden J Fielding, et al. 1999 Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group Br J Cancer 79 1522 1530 10.1038/sj.bjc.6690243 1:STN:280:DyaK1M3gt1Ortg%3D%3D 10188901
10. HH Hartgrink CJ van de Velde H Putter, et al. 2004 Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial J Clin Oncol 22 2069 2077 10.1200/JCO.2004.08. 026 1:STN:280:DC%2BD2c3ntVOgsQ%3D%3D 15082726
11. McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph node dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2003, CD001964
12. A Wolff N Davidson 2000 Primary systemic therapy in operable breast cancer J Clin Oncol 18 1558 1569 1:STN:280:DC%2BD3c3gtVGisg%3D%3D 10735905
13. JA Ajani DM Ota JM Jessup 1991 Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy Cancer 68 1501 1506 10.1002/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO;2-L 1:STN:280:DyaK3MzntFartw%3D%3D 1893349
14. JA Ajani RJ Mayer DM Ota 1993 Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma J Natl Cancer Inst 85 1839 1844 10.1093/jnci/85.22.1839 1:STN:280:DyaK2c%2FkslWgtA%3D%3D 8230264
15. JA Ajani PF Mansfield PM Lynch 1999 Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma J Clin Oncol 17 2403 2411 1:CAS:528:DyaK1MXltlylt7g%3D 10561303
16. HH Hartgrink CJH van de Velde H Putter, et al. 2004 Neo-adjuvant chemotherapy for operable gastric cancer; long-term results of the Dutch randomised FAMTX trial Eur J Surg Oncol 30 643 649 10.1016/j.ejso.2004.04.013 1:STN:280:DC%2BD2czltlelsg%3D%3D 15256239
17. V Boige J Pignon B Saint-Aubert, et al. 2007 Final results of a randomized trial comparing perioperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial Proc Am Soc Clin Oncol 25 18s abstract 4510
18. Z-X Zhang X-Z Gu W-B Yin, et al. 1998 Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC): report on 370 patients Int J Radiat Oncol Biol Phys 42 929 934 1:STN:280:DyaK1M%2FosVGmtQ%3D%3D 9869212
19. F Fiorica F Cartei M Enea, et al. 2007 The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data Cancer Treat Rev 33 729 740 10.1016/j.ctrv.2007.08.005 17935888
20. JA Ajani P Mansfield N Janjan, et al. 2004 Multiinstitutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma J Clin Oncol 22 2774 2780 10.1200/JCO.2004.01.015 1:STN:280: DC%2BD2czltFWnsg%3D%3D 15254045
21. JA Ajani PF Mansfield CH Crane, et al. 2005 Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome J Clin Oncol 23 1237 1244 10.1200/JCO.2005.01.305 1:CAS:528:DC%2BD2MXitl2gurY%3D 15718321
22. D Cunningham WH Allum SP Stenning, et al. 2006 Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11 20 10.1056/NEJMoa055531 1:CAS:528:DC%2BD28Xms1Chsrw%3D 16822992
23. Roth AD, et al.: Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized trial of the Swiss Group for Clinical Cancer Res (SAKK) and the European Institute of Oncology (EIO). World Congress of Gastrointestinal Cancers Barcelona, Spain, 2007
24. C Earle J Maroun 1999 Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials Eur J Cancer 35 7 1059 1064 10.1016/S0959-8049(99)00076-3 1:STN:280:DC%2BD3c%2FgtlKnsw%3D%3D 10533448
25. E Mari I Floriani A Tinazzi, et al. 2000 Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) Ann Oncol 11 7 837 843 10.1023/A:1008377101672 1:STN:280:DC%2BD3cvks1SgtA%3D%3D 10997811
26. S Sakuramoto M Sasako T Yamaguchi, et al. 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820 10.1056/NEJMoa072252 1:CAS:528:DC%2BD2sXht1Kit7bI 17978289
27. QS Chu LA Hammond G Schwartz, et al. 2004 Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once daily-for-28-day schedule in patients with advanced malignancies Clin Cancer Res 10 15 4913 4921 10.1158/1078-0432.CCR-04-0469 1:CAS:528:DC%2BD2cXmtlSisbk%3D 15297391
28. M Nakajima T Fukami H Yamanaka, et al. 2006 Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations Clin Pharmacol Ther 80 282 297 10.1016/j.clpt.2006.05.012 1:CAS:528:DC%2BD28XptFCnsr4%3D 16952495
29. K Fujita W Yamamoto H Endo, et al. 2007 Effects of CYP2A6 genotype and plasma level of 5-chloro-2,4-dihydroxipyridine (CDHP) on pharmacokinetics (PK) of tegafur (FT) and 5-fluorouracil (5-FU) in the patients treated by S-1 ASCO Meeting Abstracts 25 2504
30. JS Macdonald SR Smalley J Benedetti, et al. 2001 Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725 730 10.1056/NEJMoa010187 1:STN:280:DC%2BD3Mvps1Cqug%3D%3D 11547741
31. AD Wagner W Grothe J Haerting, et al. 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909 10.1200/JCO.2005.05.0245 1:CAS:528:DC%2BD28XntV2gs7s%3D 16782930
32. Van Cutsem E, Kang Y, Chung H, et al.: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Annual Meeting of ASCO 2009; abstract #LBA4509
33. T Yano T Doi A Ohtsu N Boku K Hashizume M Nakanishi, et al. 2006 Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer Oncol Rep 15 65 71 16328035